CD4 and Alzheimer disease: Research has shown that modulating biological therapy can benefit APP/PS1 and 3XTG-AD mice by activating the STAT4/JAK2/STAT5 pathways, which increases the expression of IFN-γ/IL-10 in CD4+ T lymphocytes.